# HALOZYME THERAPEUTICS, INC. (HALO) · Edgar & Edgarette company card

> Halozyme Therapeutics (HALO) grew revenue 37.6% in FY2025 to $1.4 billion, operating margin 33.6% against a -15.8% median for biological products, (no diagnostic substances), equity 1.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1159036 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/HALO) · [JSON](https://www.pops4.com/boards/company/HALO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1.4B |
| Revenue growth, 1 year | 37.6% |
| Revenue growth per year | 33.2% |
| Operating margin | 33.6% (prior year 54.3%) |
| Net margin | 22.7% |
| Operating cash flow | $652M |
| Capital spending | $7M |
| Free cash flow | $645M |
| Cash | $134M |
| Long-term debt | $2.1B |
| Total assets | $2.5B |
| Total equity | $49M |
| Equity ÷ assets | 1.9% |
| Return on equity | 649.2% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 3.02 (safe zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: -2.56 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $1.4B (FY2025), total debt $2.1B. Experience: revenue up 37.6% on the year, up 33.2% a year over 4 years; operating margin 33.6%, down from 54.3%. Soundness: equity 1.9% of assets, return on equity 649.2%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.6B and $2.1B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.5B to $2.3B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 33.6% against a -15.8% median; growth 37.6% against 21.4%.

Range logged 2026-09-26, receipt 6793ea37d174a4ba, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 8, latest 2026-09-30 ([filing](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000128/0001159036-26-000128-index.htm))

## Recent filings

- 8-K · filed 2026-09-30 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000128/0001159036-26-000128-index.htm)
- 8-K · filed 2026-09-22 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/0001193125-26-398015-index.htm)
- 8-K · filed 2026-09-18 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000126/0001159036-26-000126-index.htm)
- 8-K · filed 2026-09-16 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000121/0001159036-26-000121-index.htm)
- 8-K · filed 2026-08-18 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000106/0001159036-26-000106-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1159036/000115903626000104/0001159036-26-000104-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001159036.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1159036

## Cite

POPS4, Edgar & Edgarette: HALOZYME THERAPEUTICS, INC. (HALO) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/HALO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.